Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
85Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $8.54B | $1.07B | $3.53 |
| 2024 | $7.51B | $1.00B | $3.34 |
| 2023 | $7.46B | $887.00M | $3.01 |
| 2022 | $8.60B | $837.00M | $2.84 |
| 2021 | $7.33B | $1.35B | $4.66 |
Social Signal Score
Earnings
Thu, Oct 29(in 2 months)
Consensus estimate $1.12 per share
Typical surprise +2.7% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Jul 28$0.37 vs $0.36beat
- Tue, Apr 28$1.13 vs $1.10beat
- Thu, Feb 5$0.95 vs $0.93beat
- Thu, Oct 30$0.93 vs $0.86beat
- Thu, Jul 31$0.71 vs $0.68beat
- Thu, Apr 24$1.02 vs $1.01beat
Estimates and results for CMS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from CMS's reported EPS growth of -6.7% a year over 4 years.
- EPS in 5 years
- $2.52
- Implied price
- $50.38
- Return from $71.11
- -6.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $25.05 — -64.8% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 14 | 17 | 20 | 23 | 26 |
|---|---|---|---|---|---|
| -16.7% | -22.4% | -19.3% | -16.7% | -14.3% | -12.2% |
| -11.7% | -17.7% | -14.5% | -11.7% | -9.2% | -6.9% |
| -6.7% | -13.1% | -9.6% | -6.7% | -4.0% | -1.6% |
| -1.7% | -8.4% | -4.8% | -1.7% | 1.1% | 3.6% |
| 3.3% | -3.8% | 0.0% | 3.3% | 6.3% | 8.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (2)
- News (RSS)zerohedge·2d ago·Negative
…s and sex-change surgeries for children. Mental health treatment for gender dysphoria and other conditions will remain eligible for coverage under Medicaid and CHIP. CMS Administrator Dr. Mehmet Oz said the policy reflects the administration’s effort to protect children from medical interventions whose long-term effects remain uncertain. “Children deserve our protection, not experimental interventions that pose serious risks and convey no proven benefits,” Oz said. “By cutting off federal funds …
View source ↗ - News (RSS)seekingalpha·4d ago·Neutral
Ceribell expects $114M-$117M 2026 revenue as CMS finalizes delirium NTAP up to $2,171 per patient
View source ↗